Telormedix initiates Phase I/II clinical study of TMX-101 for treating NMIBC
March 11, 2016
"This trial marks a very significant milestone for Telormedix. In less than three years we have managed to advance our programmes to take our first product lead into the clinic which is a substantial achievement in our sector."
"Bladder cancer has the fifth highest incidence of any cancer and due to its high recurrence rate the prevalence exceeds that of almost all other cancer types including prostate cancer, breast cancer, colon cancer and lung cancer. This high recurrence rate implies that better therapy after TUR is a high unmet medical need with substantial economic consequences," said the principal investigator, Prof. Witjes, a urologist at the Radboud University Nijmegen Medical Center, "Initial laboratory and animal studies have shown significant efficacy of TMX-101 so the clinical expectations are high. If the clinical trials are successful, TMX-101 could be the very first targeted therapy dedicated to this disease."